Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
- Multi-Center
- Randomized
- Open-Label Study of single agent IMO-2055
- Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)